RuiFeng Bio Completes Nearly RMB 100 Million Series A Financing to Accelerate Gene Editing Therapy Development

VCBeat (WeChat ID: vcbeat) has learned that Ruifeng Biology recently announced the completion of its nearly RMB 100 million Series A financing round. As a leading gene-editing therapy company with core technologies and intellectual property rights, Ruifeng Biology stated that the proceeds from this financing will be used to continue advancing the research and development of its existing innovative therapies, accelerate technological iteration, and strengthen its talent infrastructure. The round was led by Alwin Investment, a renowned institution in the life sciences sector, with continued participation from existing shareholder Legendstar Capital. Qiangyun Capital served as the exclusive financial advisor for this financing.

Rejuvenate Biotech is dedicated to the development of novel therapeutics centered on gene-editing technologies. Its team is among the first internationally to apply gene editing in exploring treatments for genetic diseases, having achieved pioneering results in areas such as thalassemia and inherited ocular disorders. The company has amassed extensive expertise in editing system innovation, the construction of novel murine and large mammalian models, and multi-level efficacy evaluation.Currently in a phase of rapid growth, Rejuvenate Biotech’s management team comprises internationally renowned scientists in the field of gene editing, returning experts with research experience at top-tier overseas clinical institutions, and entrepreneurs with proven success in the gene therapy industry. The company boasts an innovative technical team spanning early discovery, pharmaceutics and clinical development, quality assurance, and intellectual property. It has established two major drug innovation platforms: ex vivo cell therapy and in vivo therapeutics.Rejuvenate Biotech’s mission is to provide accessible and curative medicines to patients with severe diseases, leveraging revolutionary gene-editing technologies. The company has built a pipeline across hematologic, ophthalmic, respiratory, and central nervous system indications. Notably, its most advanced candidate—a gene-editing therapy for β-thalassemia—demonstrates core parameters that are leading internationally.

“The completion of this financing will continue to strongly support Ruifeng Biotech’s rapid growth, helping the company secure a leading advantage in its industry development,” said Liang Junbin, Founder and CEO of Ruifeng Biotech. “Gene-editing therapeutics represent an emerging frontier in gene-based medicine, offering the potential for one-time administration with lifelong curative effects. This field is developing rapidly, and multiple early-stage clinical datasets have demonstrated the superior curative value and high safety profile of this technology. Gene editing brings hope to many patients suffering from diseases that are currently untreatable or respond poorly to existing therapies. This aligns with Ruifeng Biotech’s mission. As a very young therapeutic modality, it still requires concerted efforts across the entire industry. We extend our gratitude to Alwin Investment and Legendstar Capital, our forward-looking professional venture capital firms and existing shareholders, for their recognition and support of Ruifeng Biotech.”

As the lead investor in this funding round, Liu Jiayun, Investment Director at Alwin Capital, stated, “CRISPR gene-editing tools, as a revolutionary technology in the life sciences sector, hold immense potential for new drug development. This forms the scientific foundation for Alwin Capital’s strategic focus on the gene-editing landscape. We are delighted to invest in Rayvent Biosciences and to have the opportunity to support the company’s technological innovation and clinical translation. Dr. Liang Junbin, founder of Rayvent, possesses the rare combination of extensive R&D expertise and entrepreneurial experience. Under Dr. Liang’s leadership, we look forward to Rayvent Biosciences accelerating its R&D pipeline and bringing the benefits of science to humanity at an early date.”

As an existing shareholder of the company and a participant in this additional investment round, Leng Yan, Partner at Legendstar Capital, stated: “Legendstar Capital has long focused on innovative drug technologies in the healthcare sector. We believe that the industrialization of gene editing will provide more reliable therapeutic options for human diseases. As Ruifeng’s angel investor, we are delighted to see the progress the company has made in project development and system building over the past year since our initial investment. We also congratulate the company on completing this new round of financing and introducing institutional investors with extensive industry experience. We look forward to further progress and good news in the future.”

As the exclusive financial advisor for this round of financing, Yan Guopei, Vice President of Qiangyun Capital, stated, “Gene editing is currently the most prominent topic in the life sciences sector. The awarding of this year’s Nobel Prize in Chemistry to scientists and entrepreneurs in the field of gene editing has accelerated industry expectations regarding the commercialization of this technology. We are pleased to have facilitated the collaboration between Ruifeng Bio and renowned investment institutions in this financing round, and we remain committed to providing long-term support for Ruifeng Bio’s development.”

Alwin Capital is a specialized fund focused on early-stage investments in the life sciences sector. Driven by professional research and guided by scientific disciplines, Alwin Capital systematically invests in innovative drug development and breakthrough diagnostic technologies within the life sciences field. Committed to long-term investment in life sciences, Alwin Capital seeks excess returns grounded in deep scientific insight. Established in 2015, its core management team possesses extensive investment and research backgrounds in the healthcare and pharmaceutical industries. To date, Alwin Capital has invested in more than 20 companies in the life sciences sector, cultivating leading enterprises across multiple sub-sectors.

Legendstar Capital is a venture capital fund specializing in early-stage investments in technology-driven enterprises. Since 2010, it has identified healthcare as a key investment focus, prioritizing areas such as novel biologics and therapies, gene technologies and services, diagnostic technologies and high-value consumables, and digital health. To date, Legendstar Capital has invested in nearly 100 high-quality healthcare projects, including Axonics (NASDAQ: AXNX), Kintor Pharmaceutical (9939.HK), Burning Rock Biotech (NASDAQ: BNR), Ribo Life Science, PegBio, CoYDx, Keymed Biosciences, Gaocheng Biopharma, and Deepwise AI.